Home › Research › Down syndrome and Alzheimer's
(1)H-MRS metabolites in adults with Down syndrome: Effects of dementia
Lin AL, Powell D, Caban-Holt A, Jicha G, Robertson W, Gold BT, Davis R, Abner E et al.. NeuroImage. Clinical, 2016-06-02
Topic: Brain proteins, microglia and lab models
Plain-language summary
To determine if proton magnetic resonance spectroscopy ((1)H-MRS) detect differences in dementia status in adults with Down syndrome (DS), we used (1)H-MRS to measure neuronal and glial metabolites in the posterior cingulate cortex in 22 adults with DS and in 15 age- and gender-matched healthy controls. We evaluated associations between (1)H-MRS results and cognition among DS participants. Neuronal biomarkers, including N-acetylaspartate (NAA) and glutamate-glutamine complex (Glx), were significantly lower in DS patients with Alzheimer's should probably be changed to Alzheimer (without ' or s) through ms as per the new naming standard disease (DSAD) when compared to non-demented DS (DS) and healthy controls (CTL). Neuronal biomarkers therefore appear to reflect dementia status in DS. In contrast, all DS participants had significantly higher myo-inositol (MI), a putative glial biomarker, compared to CTL. Our data indicate that there may be an overall higher glial inflammatory component in DS compared to CTL prior to and possibly independent of developing dementia. When computing the NAA to MI ratio, we found that presence or absence of dementia could be distinguished in DS. NAA, Glx, and NAA/MI in all DS participants were correlated with scores from the Brief Praxis Test and the Severe Impairment Battery. (1)H-MRS may be a useful diagnostic tool in future longitudinal studies to measure AD progression in persons with DS. In particular, NAA and the NAA/MI ratio is sensitive to the functional status of adults with DS, including prior to dementia.
What this study adds
Evidence grade: Moderate
This is a follow-up (cohort) study of 22 participants. This study found that certain brain metabolites measured by magnetic resonance spectroscopy differ in adults with Down syndrome who have dementia compared to those without. It suggests these measures may be useful for diagnosis in future studies, but it does not test any treatment or cure.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Lin, A. L., Powell, D., Caban-Holt, A., Jicha, G., Robertson, W., Gold, B. T., et al. (2016). (1)H-MRS metabolites in adults with Down syndrome: Effects of dementia. NeuroImage. Clinical. https://doi.org/10.1016/j.nicl.2016.06.001
Vancouver
Lin AL, Powell D, Caban-Holt A, Jicha G, Robertson W, Gold BT, et al. (1)H-MRS metabolites in adults with Down syndrome: Effects of dementia. NeuroImage. Clinical. 2016. doi:10.1016/j.nicl.2016.06.001. PMID: 27330972.
BibTeX
@article{lin2016-27330972,
author = {Lin, A. L. and Powell, D. and Caban-Holt, A. and Jicha, G. and Robertson, W. and Gold, B. T. and Davis, R. and Abner, E. and others},
title = {{(1)H-MRS metabolites in adults with Down syndrome: Effects of dementia}},
journal = {NeuroImage. Clinical},
year = {2016},
doi = {10.1016/j.nicl.2016.06.001},
pmid = {27330972},
url = {https://doi.org/10.1016/j.nicl.2016.06.001}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- We evaluated associations between (1)H-MRS results and cognition among DS participants.
- Neuronal biomarkers, including N-acetylaspartate (NAA) and glutamate-glutamine complex (Glx), were significantly lower in DS patients with Alzheimer's should probably be changed to Alzheimer (without ' or s) through ms as per the new naming standard disease (DSAD) when compared to non-demented DS (DS) and healthy controls (CTL).
- In contrast, all DS participants had significantly higher myo-inositol (MI), a putative glial biomarker, compared to CTL.
- Our data indicate that there may be an overall higher glial inflammatory component in DS compared to CTL prior to and possibly independent of developing dementia.
- When computing the NAA to MI ratio, we found that presence or absence of dementia could be distinguished in DS.
Why it matters
This study found that certain brain metabolites measured by magnetic resonance spectroscopy differ in adults with Down syndrome who have dementia compared to those without. It suggests these measures may be useful for diagnosis in future studies, but it does not test any treatment or cure.
Study details
- Study designlongitudinal study
- Participants22
- Evidence strengthModerate
How this study scored 53/100
Published in a peer-reviewed journal, and it is a longitudinal study following the same people over time. Scored zero for effect reported and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (NeuroImage. Clinical) |
| Journal's citation record | 1 / 4 | NeuroImage Clinical: journal h-index 133 (OpenAlex, 2026-10-29) |
| Study design | 7 / 12 | A longitudinal study following the same people over time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2016 — within 20 year(s) of the newest study here |
| Sample size | 1 / 4 | 22 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 4 / 7 | Cited 44 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 3.7 citations a year over 12 year(s) since 2016 |
| Impact for its field and year | 3 / 6 | Cited 4.5× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 5 other studies in this library |
| Still being cited | 1 / 4 | Cited 4 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Elizabeth Head: h-index 98 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | University of Kentucky: institution h-index 824 (OpenAlex) |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 27330972) |
| Free to read | 2 / 2 | Free to read |
| Total | 53 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1016/j.nicl.2016.06.001
- PubMed: 27330972
- Original source →
- Free full text: NeuroImage Clinical →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
5 studies in the alzhub library list this one in their references.
Related studies in Down syndrome and Alzheimer's from nearby years
Also tagged “down”
527 studies in the library carry the topic tag “down”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 527 tagged studies.